Latest news

• Sanofi extends growth spurt thanks to Genzyme, Dupixent

  CSCC) in the US last September. ... CSCC is a rare cancer with no other approved therapies, and that niche positioning helped sales reach $15m in the fourth-quarter, ahead of estimates and booked by Regeneron, Sanofi’s

• Orphan drugs dominate FDA's record-breaking year

  myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)

• As France protests, Sanofi takes axe to 670 jobs

  dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

• Dupixent helps put Sanofi back on growth track

  Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

• Sanofi’s latecomer PD-1 gets date for FDA verdict

  The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Regeneron-partnered cemiplimab is the first of the